Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Empliciti Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentClover HealthPolicy 4858-A

    Standard Medicare Part B Management Empliciti

    Customize your policy alerts

    Sign up for clover_health Policy 4858-A alerts

    Get alerted when Policy 4858-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Empliciti (elotuzumab), including FDA-approved and specified compendial uses, for Clover Health Medicare Part B members. Coverage applies when the applicable disease, prior-therapy, combination-regimen, and continuation criteria are met.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Empliciti
    Policy CodePolicy 4858-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit supporting evidence from Medicare-approved compendia for indications not listed in the policy criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization duration
    2FDA-approved multiple myeloma indications
    4Listed compendial uses
    3Combination regimens allowed

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Previously Treated Multiple Myeloma

    Authorization of 12 months may be granted for the treatment of previously treated multiple myeloma when ANY of the following criteria are met:

    ANY of the following

    • The requested medication will be used in combination with lenalidomide and dexamethasone
    • The requested medication will be used in combination with bortezomib and dexamethasone
    • The requested medication will be used in combination with pomalidomide and dexamethasone in members who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor

    POEMS, MIDD, and MGRS

    Authorization of 12 months may be granted for the treatment of POEMS, plasma-cell related MIDD, or plasma cell-related MGRS when ANY of the following criteria are met:

    ANY of the following

    • The requested medication will be used in combination with lenalidomide and dexamethasone
    • The requested medication will be used in combination with bortezomib and dexamethasone
    • The requested medication will be used in combination with pomalidomide and dexamethasone in members who have received at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor

    Continuation Therapy

    All members, including new members, requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent. Authorization of 12 months may be granted when ALL of the following criteria are met:

    ALL of the following

    • The member is currently receiving therapy with Empliciti
    • Empliciti is being used to treat an indication in the coverage criteria section
    • Benefit from therapy

      • No unacceptable toxicity while on the current regimen
      • No evidence of disease progression while on the current regimen

    Covered Combination Regimens

    RegimenCovered indicationsPrior-therapy requirementCoverage
    Empliciti + lenalidomide + dexamethasonePreviously treated multiple myeloma; POEMS; plasma-cell related MIDD; plasma-cell related MGRSNo additional prior-therapy requirement stated in the coverage criterionCovered
    RegimenCovered indicationsPrior-therapy requirementCoverage
    Empliciti + bortezomib + dexamethasonePreviously treated multiple myeloma; POEMS; plasma-cell related MIDD; plasma-cell related MGRSNo additional prior-therapy requirement stated in the coverage criterionCovered
    RegimenCovered indicationPrior-therapy requirementCoverage
    Empliciti + pomalidomide + dexamethasoneMultiple myeloma; POEMS; plasma-cell related MIDD; plasma-cell related MGRSAt least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor; for the FDA-approved multiple myeloma indication, prior therapies include lenalidomide and a proteasome inhibitorCovered

    Authorization and Documentation Guidance

    Prior Authorization

    Initial Authorization

    Prior authorization is required for Empliciti. Authorization for up to 12 months may be granted for previously treated multiple myeloma, POEMS syndrome, plasma cell-related MIDD, or plasma cell-related MGRS when at least one approved combination regimen criterion is met.

    • For multiple myeloma, use in combination with lenalidomide and dexamethasone; bortezomib and dexamethasone; or pomalidomide and dexamethasone after at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor.
    • For POEMS, MIDD, or MGRS, use in combination with lenalidomide and dexamethasone; bortezomib and dexamethasone; or pomalidomide and dexamethasone after at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor.
    Prior Authorization

    Continuation Authorization Requirements

    For continuation requests, including requests from new members, the member must be currently receiving Empliciti. Authorization for up to 12 months may be granted when all continuation criteria are met.

    • The member is currently receiving therapy with Empliciti.
    • Empliciti is being used to treat an indication listed in the coverage criteria.
    • The member is benefiting from therapy, with no unacceptable toxicity on the current regimen and no evidence of disease progression on the current regimen.

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Continuation Requirements Not Met

    Continuation authorization may be denied when the member is not currently receiving Empliciti, Empliciti is not being used for an indication in the coverage criteria, or the member is not benefiting from therapy.

    • Deny or do not continue authorization if there is unacceptable toxicity on the current regimen.
    • Deny or do not continue authorization if there is evidence of disease progression on the current regimen.
    • The member must be currently receiving Empliciti, including when the request is submitted by a new member.

    Policy Background

    Empliciti (elotuzumab) is covered under this Medicare Part B policy when used in combination regimens for previously treated multiple myeloma and selected plasma-cell disorders. Covered partner regimens include lenalidomide with dexamethasone, bortezomib with dexamethasone, and pomalidomide with dexamethasone; the pomalidomide regimen requires at least two prior therapies, including an immunomodulatory agent and a proteasome inhibitor.

    The selected plasma-cell disorders addressed by this policy are POEMS syndrome, plasma-cell-related monoclonal immunoglobulin deposition disease (MIDD), and plasma-cell-related monoclonal gammopathy of renal significance (MGRS). Initial and continuation authorization may be granted for 12 months when the applicable indication, regimen, prior-therapy, and clinical-benefit requirements are met.

    Definitions

    Benefit from therapy
    DefinitionBenefit from therapy means no unacceptable toxicity while on the current regimen and no evidence of disease progression while on the current regimen.
    ToxicityThe member must have no unacceptable toxicity while receiving the current regimen.
    Disease statusThe member must have no evidence of disease progression while receiving the current regimen.
    Empliciti
    Product nameEmpliciti
    Generic nameElotuzumab
    Product applicabilityThe policy applies to both brand and generic products.
    Dosage forms and strengthsAll dosage forms and strengths are included unless otherwise stated.
    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Empliciti
    Policy CodePolicy 4858-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit supporting evidence from Medicare-approved compendia for indications not listed in the policy criteria.
    SourceLink
    On This Page
    Coverage CriteriaCovered Combination RegimensAuthorization and Documentation GuidancePolicy BackgroundDefinitions